Table 1.
Clinicopathologic features of BC patients and the levels of DBCCR1-003 and DNMT1 expression in the cancer tissues
| Characteristic | Number of patients | Molecular expression level | |||
|---|---|---|---|---|---|
| DBCCR1-003c | p value | DNMT1d | p value | ||
| All patients | 24 (100 %) | ||||
| Gendera | 0.403 | 0.639 | |||
| Females | 10 (41.6 %) | 4.61 (1.10–4.19) | 1.68 (1.2–2.39) | ||
| Males | 14 (58.4 %) | 1.60 (0.56–3.70) | 1.87 (0.65–3.43) | ||
| Age at diagnosisa | 0.887 | 0.931 | |||
| ≤70 years | 12 (50.0 %) | 2.0 (0.58–3.70) | 1.85 (0.65–3.43) | ||
| >70 years | 12 (50.0 %) | 1.91 (0.56–4.19) | 1.74 (0.97–2.39) | ||
| Pathologic gradea | 0.02* | 0.035* | |||
| Low grade | 8 (33.3 %) | 2.90 (1.39–4.19) | 1.4 (0.97–2.19) | ||
| High grade | 16 (66.7 %) | 1.39 (0.57–2.81) | 1.98 (1.15–3.43) | ||
| Pathologic stageb | 0.14 | 0.037* | |||
| pTa | 5 (20.8 %) | 3.39 (2.51–4.19) | 1.26 (0.65–1.84) | ||
| pT1 | 13 (54.2 %) | 1.84 (0.66–3.70) | 1.74 (1.0–2.39) | ||
| ≥pT2 | 6 (25.0 %) | 1.02 (0.57–1.57) | 2.34 (1.35–2.71) | ||
* Significant difference
aEvaluated with the Mann–Whitney U-test
bEvaluated with the Kruskal–Wallis test
cLevels of DBCCR1-003 expression were determined by qRT–PCR assay, and normalized to the U6 levels using the 2−△CT△CT method
dLevels of DNMT1 expression were determined by qRT–PCR assay, and normalized to the GAPDH levels using the 2−△CT△CT method